SARS-CoV-2 virus less likely to develop resistance to molnupiravir: Gagandeep Kang

Preliminary data, which is yet to be peer-reviewed, shows molnupiravir can reduce risk of hospitalisation or death by 50% in non-hospitalised adult patients with mild-to-moderate COVID-19 disease. The trial included only those older than 60 years and have at least one comorbidity. On October 11, just 10 days after Merck announced via a press release … Continue reading SARS-CoV-2 virus less likely to develop resistance to molnupiravir: Gagandeep Kang

India ill prepared despite lessons learnt in the first wave

After painfully negotiating numerous hurdles during the first wave that peaked in mid-September last year, India appears to have learnt little as more ferocious second wave is ravaging the country. After painfully negotiating numerous hurdles during the first wave that peaked in mid-September last year, India appears to have learnt little as more ferocious second … Continue reading India ill prepared despite lessons learnt in the first wave

How the new coronavirus variant quickly accumulated 17 mutations

Immunocompromised patients experiencing prolonged infection with novel coronavirus when treated with convalescent plasma might trigger a strong selective pressure on the virus due to high concentration of antibodies. This might lead to the generation of large number of mutations. The new SARS-CoV-2 variant — B.1.1.7 — that was first seen in Kent and Greater London … Continue reading How the new coronavirus variant quickly accumulated 17 mutations

WHO supported Solidarity trial finds remdesivir ineffective but WHO prequalifies it anyway

Even as WHO supported Solidarity Therapeutics Trial found remdesivir to be ineffective in reducing mortality and duration of hospital stay, the global body prequalified the drug the same day the results of the trial were posted on the preprint server. And Gilead Sciences, which was aware of the Solidarity trial results, signed a $1 billion … Continue reading WHO supported Solidarity trial finds remdesivir ineffective but WHO prequalifies it anyway

Remdesivir, other repurposed drugs ineffective, says WHO’s Solidarity trial

WHO's Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the pandemic, has found that four repurposed drugs — remdesivir, interferon, hydroxychloroquine and lopinavir/ritonavir regimes — for the treatment of COVID-19 are not effective. WHO's Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the … Continue reading Remdesivir, other repurposed drugs ineffective, says WHO’s Solidarity trial

Gilead to begin testing inhaled remdesivir for early-stage treatment

Gilead plans to begin a Phase-1 clinical trial in August of an inhaled version of remdesivir for early-stage COVID-19 treatment outside of hospital settings. The drug is currently approved for daily intravenous administration in the hospital. With an approval from the U.S. FDA in hand, Gilead hopes to begin a Phase-1 clinical trial in August … Continue reading Gilead to begin testing inhaled remdesivir for early-stage treatment

Remdesivir drug has no significant clinical benefits for COVID-19 patients: Lancet

Treating severe COVID-19 patients with the antiviral drug remdesivir does not quicken recovery, the first randomised, placebo-controlled, double-blind trial found. Although not statistically significant, those treated with the drug within 10 days of disease onset appeared to recover faster after than those patients who got a dummy. Treating severe COVID-19 patients with the antiviral drug … Continue reading Remdesivir drug has no significant clinical benefits for COVID-19 patients: Lancet